Conference data: VIALE-A Phase III RCT of venetoclax plus azacitidine demonstrates survival benefits in untreated AML

Patients with acute myeloid leukaemia (AML; n=433) who were treated with the combination achieved improved median overall survival (14.7 vs 9.6 months) and a 34% reduction in the risk of death (HR 0.66; P=0.001) vs azacitidine.


Biospace Inc.